Consolidated Financial Results
for the First Quarter of the Fiscal Year Ending March 31, 2025 (IFRS)

July 31, 2024

Company name	: **ONO PHARMACEUTICAL CO., LTD.**
Listing	: Tokyo Stock Exchange
Securities code	: 4528
URL	: https://www.ono-pharma.com/en
Representative	: Toichi Takino Representative Director, President and Chief Operating Officer
Inquiries	: Ryuta Imura Senior Director of Corporate Communications
Telephone	: +81-(0)6-6263-5670
Scheduled date of dividend payment commencement	: ―
Supplementary materials for quarterly financial results	: Yes
Earnings announcement for quarterly financial results	: Yes (for institutional investors and securities analysts)

(Note: Amounts of less than one million yen are rounded.)

1. Consolidated Financial Results for the First Quarter of FY 2024 (From April 1, 2024 to June 30, 2024)

(1) Consolidated Operating Results (cumulative)

(% change from the same period of the previous fiscal year)

	Revenue		Operating profit		Profit before tax		Profit for the period		Profit attributable to owners of the Company		Total comprehensive income for the period	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%
FY 2024 Q1	117,675	(1.9)	30,690	(25.8)	33,310	(21.4)	24,835	(21.9)	24,794	(22.1)	36,595	(5.4)
FY 2023 Q1	120,016	12.5	41,348	8.3	42,378	8.5	31,818	7.8	31,818	7.9	38,701	30.3

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
FY 2024 Q1	52.79	52.75
FY 2023 Q1	65.16	65.15

(2) Consolidated Financial Position

	Total assets	Total equity	Equity attributable to owners of the Company	Ratio of equity attributable to owners of the Company to total assets
	Million yen	Million yen	Million yen	%
As of June 30, 2024	1,083,697	816,413	810,731	74.8
As of March 31, 2024	913,668	798,604	792,961	86.8

2. Dividends

	Annual dividends per share				
	End of first quarter	End of second quarter	End of third quarter	End of fiscal year	Total
	Yen	Yen	Yen	Yen	Yen
FY 2023	―	40.00	―	40.00	80.00
FY 2024	―				
FY 2024 (Forecast)		40.00	―	40.00	80.00

(Note) Revisions to dividend forecast most recently announced: None

3. Consolidated Financial Forecast for FY 2024 (April 1, 2024 to March 31, 2025)

(% change from the previous fiscal year)

	Revenue		Operating profit		Profit before tax		Profit for the year		Profit attributable to owners of the Company		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
FY 2024	450,000	(10.5)	122,000	(23.7)	123,000	(24.9)	91,200	(28.8)	91,000	(28.9)	193.76

(Note) Revisions to financial forecast most recently announced: None

Notes

(1) Significant changes in scope of consolidation during the period: Yes
Newly included: 12 companies (Company name) Deciphera Pharmaceuticals, Inc.
Other subsidiaries (11 companies)

(2) Changes in accounting policies and changes in accounting estimates
1) Changes in accounting policies required by IFRS: None
2) Changes in accounting policies due to other than (2) – 1) above: None
3) Changes in accounting estimates: None

(3) Number of shares issued and outstanding (common stock)
1) Number of shares issued and outstanding as of the end of the period (including treasury shares):

As of June 30, 2024	498,692,800	shares
As of March 31, 2024	498,692,800	shares

2) Number of treasury shares as of the end of the period:

As of June 30, 2024	29,048,072	shares
As of March 31, 2024	29,045,346	shares

3) Average number of shares outstanding during the period:

Three months ended June 30, 2024	469,644,182	shares
Three months ended June 30, 2023	488,332,722	shares

* Review of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

* Note to ensure appropriate use of forecasts, and other comments in particular
Forecasts and other forward-looking statements included in this report are based on information currently available and certain assumptions that the Company deems reasonable. Actual performance and other results may differ significantly due to various factors. Please refer to "(4) Future Outlook" on page 4 for information regarding the consolidated financial forecasts.

Index of the Attachment

1. Overview of Operating Results and Other Information

(1) Overview of Operating Results for the 1st Quarter of FY 2024

(Millions of yen)

	Three months ended June 30, 2023	**Three months ended June 30, 2024**	Change	Change (%)
Revenue	120,016	**117,675**	(2,340)	(1.9%)
Operating profit	41,348	**30,690**	(10,658)	(25.8%)
Profit before tax	42,378	**33,310**	(9,068)	(21.4%)
Profit for the period (attributable to owners of the Company)	31,818	**24,794**	(7,024)	(22.1%)

[Revenue]

Revenue totaled ¥117.7 billion, which was a decrease of ¥2.3 billion (1.9%) from the corresponding period of the previous fiscal year (year on year).

- Sales of Opdivo Intravenous Infusion for malignant tumors were decreased by ¥5.7 billion (15.1%) year on year to ¥32.1 billion, mainly due to the revision of the National Health Insurance (NHI) drug price.
- Sales of Forxiga Tablets for diabetes, chronic heart failure and chronic kidney disease were increased by ¥4.6 billion (26.4%) year on year to ¥22.2 billion, mainly due to its expanded use, particularly in treatment for chronic kidney disease.
- With respect to other main products, sales of Orencia Subcutaneous Injection for rheumatoid arthritis were ¥6.9 billion (4.5% increase year on year). Sales of Glactiv Tablets for type-2 diabetes were ¥5.0 billion (10.7% decrease year on year). Sales of Velexbru Tablets for malignant tumors were ¥2.7 billion (3.9% increase year on year). Sales of Kyprolis for Intravenous Infusion for multiple myeloma were ¥2.3 billion (3.0% increase year on year). Sales of Parsabiv Intravenous Injection for Dialysis for secondary hyperparathyroidism on hemodialysis were ¥2.1 billion (0.3% decrease year on year). Sales of Ongentys Tablets for Parkinson's disease were ¥1.9 billion (23.2% increase year on year).
- Royalty and others decreased by ¥1.1 billion (2.9%) year on year to ¥38.3 billion, mainly due to a decrease in royalty revenue from Merck & Co., Inc., and others in line with a decrease in royalty rates, despite an increase in royalty revenue from Bristol-Myers Squibb Company.

[Operating Profit]

Operating profit was ¥30.7 billion, a decrease of ¥10.7 billion (25.8%) year on year.

- Cost of sales decreased by ¥0.5 billion (1.7%) year on year to ¥29.7 billion.
- Research and development costs increased by ¥4.3 billion (17.4%) year on year to ¥28.9 billion mainly due to increases in research costs and development costs for clinical trials.
- Selling, general, and administrative expenses (except for research and development costs) increased by ¥4.4 billion (18.8%) year on year to ¥27.9 billion mainly due to increases in co-promotion fees associated with expanding sales of Forxiga Tablets and expenses associated with the acquisition of Deciphera Pharmaceuticals, Inc.

[Profit for the period] (attributable to owners of the Company)

Profit attributable to owners of the Company decreased by ¥7.0 billion (22.1%) year on year to ¥24.8 billion in association with the decrease of the profit before tax.

(2) Overview of Financial Position for the 1st Quarter of FY 2024

(Millions of yen)

	As of March 31, 2024	**As of June 30, 2024**	Change
Total assets	913,668	**1,083,697**	170,030
Equity attributable to owners of the Company	792,961	**810,731**	17,770
Ratio of equity attributable to owners of the Company to total assets	86.8%	**74.8%**	
Equity attributable to owners of the Company per share	1,688.43 yen	**1,726.26 yen**	

Total assets increased to ¥1,083.7 billion by ¥170.0 billion from the end of the previous fiscal year.
Current assets decreased by ¥26.3 billion to ¥387.3 billion, mainly due to a decrease in other financial assets.
Non-current assets increased by ¥196.3 billion to ¥696.4 billion, mainly due to the recording of goodwill associated with the acquisition of Deciphera Pharmaceuticals, Inc., despite there being a decrease in other financial assets.
Liabilities increased by ¥152.2 billion to ¥267.3 billion, mainly due to the loans from financial institutions to finance the acquisition of Deciphera Pharmaceuticals, Inc.
Equity attributable to owners of the Company increased by ¥17.8 billion to ¥810.7 billion, mainly due to the recording of the profit for the period and increases in other components of equity, despite there being cash dividends.

(3) Overview of Cash Flows for the 1st Quarter of FY 2024

(Millions of yen)

	Three months ended June 30, 2023	**Three months ended June 30, 2024**	Change
Cash and cash equivalents at the beginning of the period	96,135	**166,141**	
Cash flows from operating activities	(9,638)	**813**	10,451
Cash flows from investing activities	(9,190)	**(165,196)**	(156,006)
Cash flows from financing activities	(17,536)	**131,855**	149,391
Net increase (decrease) in cash and cash equivalents	(36,364)	**(32,527)**	
Effects of exchange rate changes on cash and cash equivalents	661	**635**	
Cash and cash equivalents at the end of the period	60,433	**134,248**	

Net increase/decrease in cash and cash equivalents for the first quarter (three months) of the fiscal year 2024 was a decrease of ¥32.5 billion.
Net cash provided by operating activities was ¥0.8 billion, as a result of profit before tax of ¥33.3 billion, etc., while there were income taxes paid of ¥21.9 billion and decreases in trade and other payables of ¥7.7 billion, etc.
Net cash used in investing activities was ¥165.2 billion, as a result of the acquisition of subsidiaries of ¥364.8 billion etc., while there were proceeds from withdrawal of time deposits of ¥200.4 billion, etc.
Net cash provided by financing activities was ¥131.9 billion, as a result of an increase in short-term loans of ¥150.0 billion, while there were dividends paid of ¥17.4 billion, etc.

(4) Future Outlook

There are no changes from the consolidated financial forecast for the year ending March 31, 2025, announced on May 9, 2024.
The impact of the acquisition of Deciphera Pharmaceuticals, Inc., on the consolidated financial results is currently being reviewed.

2. Basic Approach to the Selection of Accounting Standards

Our group has applied International Financial Reporting Standards (IFRS) from the fiscal year ended March 31, 2014, for the purpose of improving comparability by disclosing financial information based on international standards and enhancing the convenience of various stakeholders such as shareholders, investors, and business partners.

3. Condensed Interim Consolidated Financial Statements and Major Notes

(1) Condensed Interim Consolidated Statement of Financial Position

(Millions of yen)

	As of March 31, 2024	As of June 30, 2024
Assets		
Current assets		
Cash and cash equivalents	166,141	134,248
Trade and other receivables	136,066	150,354
Marketable securities	—	16,670
Other financial assets	38,454	3,623
Inventories	48,629	53,282
Other current assets	24,306	29,111
Total current assets	413,596	387,288
Non-current assets		
Property, plant, and equipment	104,752	108,673
Goodwill	—	355,881
Intangible assets	57,288	56,482
Investment securities	121,147	121,301
Investments in associates	115	116
Other financial assets	173,113	8,174
Deferred tax assets	40,863	42,262
Other non-current assets	2,795	3,521
Total non-current assets	500,072	696,409
Total assets	913,668	1,083,697

(Millions of yen)

	As of March 31, 2024	As of June 30, 2024
Liabilities and Equity		
Current liabilities		
Trade and other payables	60,691	60,684
Short-term loans	—	150,000
Lease liabilities	2,310	2,889
Other financial liabilities	2,273	6,412
Income taxes payable	22,093	9,496
Other current liabilities	16,257	23,265
Total current liabilities	103,624	252,745
Non-current liabilities		
Lease liabilities	6,552	9,718
Other financial liabilities	0	0
Retirement benefit liabilities	3,294	3,251
Deferred tax liabilities	1,013	1,022
Other non-current liabilities	580	548
Total non-current liabilities	11,439	14,539
Total liabilities	115,063	267,285
Equity		
Share capital	17,358	17,358
Capital reserves	17,458	17,469
Treasury shares	(63,233)	(63,234)
Other components of equity	53,194	63,454
Retained earnings	768,183	775,684
Equity attributable to owners of the Company	792,961	810,731
Non-controlling interests	5,644	5,682
Total equity	798,604	816,413
Total liabilities and equity	913,668	1,083,697

(2) Condensed Interim Consolidated Statement of Income and Condensed Interim Consolidated Statement of Comprehensive Income

Condensed Interim Consolidated Statement of Income

(Millions of yen)

	Three months ended June 30, 2023	Three months ended June 30, 2024
Revenue	120,016	117,675
Cost of sales	(30,171)	(29,671)
Gross profit	89,844	88,004
Selling, general, and administrative expenses	(23,483)	(27,886)
Research and development costs	(24,579)	(28,857)
Other income	118	37
Other expenses	(553)	(609)
Operating profit	41,348	30,690
Finance income	1,273	2,695
Finance costs	(241)	(75)
Share of profit (loss) from investments in associates	(2)	0
Profit before tax	42,378	33,310
Income tax expense	(10,560)	(8,474)
Profit for the period	31,818	24,835
Profit for the period attributable to:		
Owners of the Company	31,818	24,794
Non-controlling interests	0	42
Profit for the period	31,818	24,835
Earnings per share:		
Basic earnings per share (Yen)	65.16	52.79
Diluted earnings per share (Yen)	65.15	52.75

Condensed Interim Consolidated Statement of Comprehensive Income

(Millions of yen)

	Three months ended June 30, 2023	Three months ended June 30, 2024
Profit for the period	31,818	24,835
Other comprehensive income:		
Items that will not be reclassified to profit or loss:		
Net gain (loss) on financial assets measured at fair value through other comprehensive income	8,479	1,257
Remeasurements of defined benefit plans	(24)	(51)
Share of net gain (loss) on financial assets measured at fair value through other comprehensive income of investments in associates	5	(1)
Total of items that will not be reclassified to profit or loss	8,460	1,206
Items that may be reclassified subsequently to profit or loss:		
Exchange differences on translation of foreign operations	1,331	12,316
Net fair value gain (loss) on cash flow hedges	(2,908)	(1,762)
Total of items that may be reclassified subsequently to profit or loss	(1,577)	10,554
Total other comprehensive income	6,883	11,760
Total comprehensive income for the period	38,701	36,595
Comprehensive income for the period attributable to:		
Owners of the Company	38,675	36,545
Non-controlling interests	26	50
Total comprehensive income for the period	38,701	36,595

(3) Condensed Interim Consolidated Statement of Changes in Equity

Three months ended June 30, 2023

(Millions of yen)

	Equity attributable to owners of the Company							
	Share capital	Capital reserves	Treasury shares	Other components of equity	Retained earnings	Total equity attributable to owners of the Company	Non-controlling interests	Total equity
Balance as of April 1, 2023	17,358	17,080	(54,161)	51,701	709,890	741,869	5,944	747,812
Profit for the period					31,818	31,818	0	31,818
Other comprehensive income				6,857		6,857	26	6,883
Total comprehensive income for the period	–	–	–	6,857	31,818	38,675	26	38,701
Purchase of treasury shares			(0)			(0)		(0)
Cash dividends					(18,068)	(18,068)	(9)	(18,077)
Share-based payments		12				12		12
Transfer from other components of equity to retained earnings				(101)	101	—		—
Total transactions with the owners	–	12	(0)	(101)	(17,967)	(18,056)	(9)	(18,065)
Balance as of June 30, 2023	17,358	17,092	(54,161)	58,457	723,741	762,487	5,961	768,449

Three months ended June 30, 2024

(Millions of yen)

	Equity attributable to owners of the Company							
	Share capital	Capital reserves	Treasury shares	Other components of equity	Retained earnings	Total equity attributable to owners of the Company	Non-controlling interests	Total equity
Balance as of April 1, 2024	17,358	17,458	(63,233)	53,194	768,183	792,961	5,644	798,604
Profit for the period					24,794	24,794	42	24,835
Other comprehensive income				11,752		11,752	8	11,760
Total comprehensive income for the period	—	—	—	11,752	24,794	36,545	50	36,595
Purchase of treasury shares			(0)			(0)		(0)
Cash dividends					(18,786)	(18,786)	(11)	(18,797)
Share-based payments		11				11		11
Transfer from other components of equity to retained earnings				(1,493)	1,493	—		—
Total transactions with the owners	—	11	(0)	(1,493)	(17,293)	(18,776)	(11)	(18,787)
Balance as of June 30, 2024	17,358	17,469	(63,234)	63,454	775,684	810,731	5,682	816,413

(4) Condensed Interim Consolidated Statement of Cash Flows

(Millions of yen)

	Three months ended June 30, 2023	Three months ended June 30, 2024
Cash flows from operating activities		
Profit before tax	42,378	33,310
Depreciation and amortization	4,530	4,379
Impairment losses	19	—
Interest and dividend income	(1,271)	(1,545)
Interest expense	23	62
(Increase) decrease in inventories	(5,316)	100
(Increase) decrease in trade and other receivables	(8,111)	(6,956)
Increase (decrease) in trade and other payables	(8,569)	(7,748)
Increase (decrease) in retirement benefit liabilities	21	(116)
Increase (decrease) in accrued consumption tax	(2,783)	(451)
Other	2,495	477
Subtotal	23,415	21,513
Interest received	8	19
Dividends received	1,233	1,198
Interest paid	(23)	(62)
Income taxes paid	(34,270)	(21,854)
Net cash provided by (used in) operating activities	(9,638)	813
Cash flows from investing activities		
Purchases of property, plant, and equipment	(1,674)	(1,544)
Proceeds from sales of property, plant, and equipment	840	5
Purchases of intangible assets	(6,068)	(1,231)
Purchases of investments	(1,187)	(385)
Proceeds from sales and redemption of investments	315	3,561
Payments into time deposits	(344)	(394)
Proceeds from withdrawal of time deposits	344	200,394
Payments for the acquisition of subsidiaries	—	(364,816)
Other	(1,416)	(785)
Net cash provided by (used in) investing activities	(9,190)	(165,196)
Cash flows from financing activities		
Net Increase (decrease) in short-term loans	—	150,000
Dividends paid	(16,827)	(17,436)
Dividends paid to non-controlling interests	(9)	(11)
Repayments of lease liabilities	(700)	(697)
Purchases of treasury shares	(0)	(0)
Net cash provided by (used in) financing activities	(17,536)	131,855
Net increase (decrease) in cash and cash equivalents	(36,364)	(32,527)
Cash and cash equivalents at the beginning of the period	96,135	166,141
Effects of exchange rate changes on cash and cash equivalents	661	635
Cash and cash equivalents at the end of the period	60,433	134,248

(5) Notes to Condensed Interim Consolidated Financial Statements

(Note Regarding Assumption of Going Concern)

Not Applicable

(Segment Information)

Segment information is omitted herein because our group's business is a single segment of the pharmaceutical business.

(Business Combination)

In April 2024, ONO Pharmaceutical, Co, Ltd. ("the Company") and Deciphera Pharmaceuticals, Inc. ("Deciphera") entered into a definitive merger agreement through a tender offer, followed by a merger of a wholly owned subsidiary of the Company with Deciphera, with Deciphera surviving as a wholly owned subsidiary of the Company (the "Acquisition"). The Acquisition was completed under the agreement on June 11, 2024 (New York City Time), making Deciphera a wholly owned subsidiary of the Company.

(1) Overview of the business combination

1. Overview of the acquired company

Company name	Deciphera Pharmaceuticals, Inc.
Business description	R&D and Commercialization of pharmaceuticals

2. Acquisition date

June 11, 2024 (New York City Time)

3. Percentage of voting equity interest acquired

100%

4. Process of obtaining control of the acquired company

Acquisition of outstanding shares in cash

5. Main objectives of the Acquisition

The Company, as a global specialty pharma company, is committed to delivering innovative new drugs to patients around the world. As a part of our medium-term management plan, the Company aims to reinforce our pipeline and accelerate global development, as well as realize direct sales in the United States and Europe. In addition, the Company has designated oncology, immunological diseases, central nervous system diseases, and specialty areas with high medical needs as priority research areas, and we accumulate disease know-how in each area to create new drugs that will bring innovation to medicine on-site. Through this Acquisition, the Company is pleased to welcome Deciphera as a partner with commercial capabilities in the United States and Europe and excellent research and development capabilities in the field of cancer. This combination will further enhance the Group's pipeline and accelerate its globalization.

Deciphera focuses on the discovery, development, and commercialization of innovative medicines for cancer and has deep expertise in kinase biology. QINLOCK® (Ripretinib), a KIT inhibitor, is approved in over 40 countries and marketed globally, including in the US, Europe, and China, for the treatment of fourth-line gastrointestinal stromal tumor (GIST). Vimseltinib, a CSF-1R inhibitor, demonstrated statistically significant and clinically meaningful efficacy across all primary and secondary endpoints in the Phase III MOTION trial in patients with tenosynovial giant cell tumor (TGCT). Data from the MOTION trial will be used to support marketing applications in the US and EU in 2024. Deciphera has established highly successful commercial operations in the United States and key European countries, which could be immediately leveraged for vimseltinib, if approved.

With this Acquisition, the Group will expand its oncology pipeline with near-term revenue growth, notably through the immediate addition of QINLOCK® and potential addition of vimseltinib. Moreover, acquiring Deciphera's commercial capabilities in the United States and Europe will strengthen the Group's global commercial presence. By leveraging Deciphera's drug discovery capabilities, the Group will further accelerate its research and development capabilities in the field of oncology.

(2) Fair value of assets acquired, liabilities assumed and purchase consideration transferred at the acquisition date are as follows:

(Millions of yen)

Cash and cash equivalents	15,433
Trade and other receivables	6,729
Marketable securities	16,650
Inventories	4,478
Property, plant, and equipment	5,182
Investment securities	1,156
Other assets	4,332
Trade and other payables	(8,941)
Lease liabilities	(3,890)
Other liabilities	(5,790)
Fair value of assets acquired and liabilities assumed (Net)	35,338
Basis adjustments	1,886
Goodwill *2	344,911
Total	382,135
Total fair value of purchase consideration transferred	382,135

Notes: 1. As of June 30, 2024, the amount of generated goodwill and the assets acquired and liabilities assumed at the acquisition date are provisionally accounted for because the review to verify the identifiable assets and liabilities at the acquisition date is still in progress and the allocation of consideration for acquisition has not been finalized.
2. Goodwill was mainly attributable to expected future earnings potential. No portion of the recognized goodwill is expected to be deductible for tax purposes.

(3) Cash flow information

(Millions of yen)

Total fair value of purchase consideration transferred	382,135
Cash and cash equivalents held by the acquiree	(15,433)
Basis adjustments	(1,886)
Payments for the acquisition of subsidiaries	364,816

(4) Acquisition-related costs

3,288 million yen

Acquisition-related costs have been recorded as “selling, general, and administrative expenses” in the consolidated statement of income for the fiscal year ended March 31, 2024, and for the three months ended June 30, 2024.

(Significant Subsequent Events)

Not Applicable

4. Supplementary Information

(1) Sales Revenue and Forecasts of Major Products

(Billions of yen)

Product name	**Three months ended June 30, 2024 (April 1, 2024 to June 30, 2024)**			**FY 2024 Forecast (April 1, 2024 to March 31, 2025)**		
	Result	YoY		**Forecast**	YoY	
		Change	Change (%)		Change	Change (%)
Opdivo Intravenous Infusion	**32.1**	(5.7)	(15.1%)	**125.0**	(20.5)	(14.1%)
Forxiga Tablets	**22.2**	4.6	26.4%	**83.0**	6.9	9.0%
Orencia for Subcutaneous Injection	**6.9**	0.3	4.5%	**27.0**	1.2	4.5%
Glactiv Tablets	**5.0**	(0.6)	(10.7%)	**18.5**	(2.7)	(12.7%)
Velexbru Tablets	**2.7**	0.1	3.9%	**10.0**	(0.2)	(2.1%)
Kyprolis for Intravenous Infusion	**2.3**	0.1	3.0%	**9.5**	0.4	3.9%
Parsabiv Intravenous Injection	**2.1**	(0.0)	(0.3%)	**8.5**	0.3	3.3%
Ongentys Tablets	**1.9**	0.4	23.2%	**7.5**	1.2	18.8%

Notes: 1. Sales revenue is shown in a gross sales basis (shipment price).
2. Regarding sales revenue forecasts for the fiscal year ending March 31, 2025, only currently approved indications are covered.

(2) Details of Sales Revenue

(Billions of yen)

	Three months ended June 30, 2023	**Three months ended June 30, 2024**
Revenue of goods and products	80.5	**79.3**
Royalty and others	39.5	**38.3**
Total	120.0	**117.7**

Note: In "Royalty and others", royalty revenue of Opdivo Intravenous Infusion from Bristol-Myers Squibb Company is included, which is ¥22.6 billion for the first quarter (three months) ended June 30, 2023, and ¥28.5 billion for the first quarter (three months) ended June 30, 2024. Royalty revenue of Keytruda® from Merck & Co., Inc. is also included, which is ¥12.2 billion for the first quarter (three months) ended June 30, 2023, and ¥6.3 billion for the first quarter (three months) ended June 30, 2024.

(3) Revenue by Geographic Area

(Billions of yen)

	Three months ended June 30, 2023	**Three months ended June 30, 2024**
Japan	78.2	**77.0**
Americas	37.1	**36.6**
Asia	3.5	**3.5**
Europe	1.1	**0.5**
Total	120.0	**117.7**

Note: Revenue by geographic area is presented on the basis of the place of customers.

(4) Main Status of Development Pipelines (Oncology)

As of July 18, 2024

<Approved> *) : "In-house" compounds include a compound generated from collaborative research.

Product Name / Development Code / Generic Name	Classification	Target Indication / Pharmacological Action	Dosage Form	Area	In-house*) / In-license
Braftovi Capsules / Encorafenib	Additional indication	Thyroid cancer *1 / BRAF inhibitor	Capsule	Japan	In-license (Pfizer Inc.)
Mektovi Tablets / Binimetinib	Additional indication	Thyroid cancer *1 / MEK inhibitor	Tablet	Japan	In-license (Pfizer Inc.)

The change from the announcement of financial results for the fiscal year ended March 31, 2024, is as follows:

*1. Approvals were obtained in Japan for Braftovi Capsules and Mektovi Tablets, for their indications and effects in doublet combination therapy for the treatment of radically unresectable BRAF-mutant thyroid cancer that has progressed after chemotherapy, as well as for the treatment of radically unresectable anaplastic BRAF-mutant thyroid cancer.

<Clinical Trial Stage>

<Opdivo> *) : "In-house" compounds include a compound generated from collaborative research.

Product Name / Development Code / Generic Name	Classification	Target Indication / Pharmacological Action	Dosage Form	Area	Phase	In-house*) / In-license
Opdivo Intravenous Infusion / Nivolumab	Additional indication	Hepatocellular carcinoma	Injection	Japan S. Korea	III	In-house (Co-development with Bristol-Myers Squibb)
	Additional indication	Bladder cancer	Injection	Japan S. Korea Taiwan	III	In-house (Co-development with Bristol-Myers Squibb)

<Yervoy> ***) :** "In-house" compounds include a compound generated from collaborative research.

Product Name / Development Code / Generic Name	Classification	Target Indication / Pharmacological Action	Dosage Form	Area	Phase	In-house*) / In-license
Yervoy Injection ★ / Ipilimumab	Additional indication	Gastric cancer	Injection	Japan S. Korea Taiwan	III	In-license (Co-development with Bristol-Myers Squibb)
	Additional indication	Urothelial carcinoma	Injection	Japan S. Korea Taiwan	III	In-license (Co-development with Bristol-Myers Squibb)
	Additional indication	Hepatocellular carcinoma	Injection	Japan S. Korea	III	In-license (Co-development with Bristol-Myers Squibb)

★: Combination with Opdivo

In the case of clinical development of the oncology drugs in the same indication, the most advanced clinical phase is described.

< ONO-4538 Subcutaneous Injection> *) : "In-house" compounds include a compound generated from collaborative research.

Product Name / Development Code / Generic Name	Classification	Target Indication / Pharmacological Action	Dosage Form	Area	Phase	In-house*) / In-license
ONO-4538 HSC	New chemical entities	Solid tumor	Injection	Japan	I	In-license (Co-development with Bristol-Myers Squibb)

<I-O Related> *) : "In-house" compounds include a compound generated from collaborative research.

Product Name / Development Code / Generic Name	Classification	Target Indication / Pharmacological Action	Dosage Form	Area	Phase	In-house*) / In-license
ONO-4578 ★	New chemical entities	Gastric cancer / Prostaglandin receptor (EP4) antagonist	Tablet	Japan S. Korea Taiwan	II	In-house
ONO-4482 ★ (BMS-986016) / Relatlimab	New chemical entities	Hepatocellular carcinoma / Anti-LAG-3 antibody	Injection	Japan S. Korea Taiwan	II	In-license (Co-development with Bristol-Myers Squibb)
	New chemical entities	Melanoma / Anti-LAG-3 antibody	Injection	Japan	I / II	In-license (Co-development with Bristol-Myers Squibb)
ONO-7427 ★	New chemical entities	Solid tumor / Anti-CCR8 antibody	Injection	Japan	I / II	In-license (Co-development with Bristol-Myers Squibb)
ONO-7475 ★ / Tamnorzatinib	New chemical entities	Pancreatic cancer / Axl/Mer inhibitor	Tablet	Japan	I	In-house
ONO-4578 ★	New chemical entities	Colorectal cancer / Prostaglandin receptor (EP4) antagonist	Tablet	Japan	I	In-house
	New chemical entities	Pancreatic cancer / Prostaglandin receptor (EP4) antagonist	Tablet	Japan	I	In-house
	New chemical entities	Non-small cell lung cancer / Prostaglandin receptor (EP4) antagonist	Tablet	Japan	I	In-house
ONO-7913 ★ / Magrolimab	New chemical entities	Pancreatic cancer / Anti-CD47 antibody	Injection	Japan	I	In-license (Gilead Sciences, Inc.)
	New chemical entities	Colorectal cancer / Anti-CD47 antibody	Injection	Japan	I	In-license (Gilead Sciences, Inc.)
ONO-7914 ★	New chemical entities	Solid tumor / STING agonist	Injection	Japan	I	In-house

★: Combination with Opdivo

The changes from the announcement of financial results for the fiscal year ended March 31, 2024, are as follows:

* Regarding the combination therapy of Opdivo and Rucaparib, a PARP inhibitor, the Group participated in a global cooperative phase III trial from Japan, South Korea, and Taiwan, targeting maintenance therapy after initial chemotherapy for ovarian cancer, which was led by Pharmaand GmbH. However, the trial was unable to achieve the primary endpoint of progression-free survival (PFS).

In the case of clinical development of the oncology drugs in the same indication, the most advanced clinical phase is described.

<Others> ***) :** "In-house" compounds include a compound generated from collaborative research.

Product Name / Development Code / Generic Name	Classification	Target Indication / Pharmacological Action	Dosage Form	Area	Phase	In-house*) / In-license
ONO-4059 / Tirabrutinib Hydrochloride	New chemical entities	Primary central nervous system lymphoma / BTK inhibitor	Tablet	USA	II	In-house
ONO-7475 / Tamnorzatinib	New chemical entities	EGFR-mutated non-small cell lung cancer / Axl/Mer inhibitor	Tablet	Japan	I	In-house
ONO-4578	New chemical entities	Hormone receptor-positive, HER2-negative breast cancer / Prostaglandin receptor (EP4) antagonist	Tablet	Japan	I	In-house
ONO-4685	New chemical entities	T-cell lymphoma / PD-1 x CD3 bispecific antibody	Injection	Japan USA	I	In-house
ONO-7018	New chemical entities	Non-Hodgkin lymphoma, Chronic lymphocytic leukemia / MALT1 inhibitor	Tablet	USA	I	In-license (Chordia Therapeutics Inc.)
ONO-8250	New chemical entities	HER2-expressing solid tumors / iPS cell-derived HER2-targeted CAR-T cell therapeutics	Injection	USA	I	In-house (Co-developed with Fate Therapeutics, Inc.)

In the case of clinical development of the oncology drugs in the same indication, the most advanced clinical phase is described.

(5) Main Status of Development Pipelines (Areas other than Oncology)

As of July 18, 2024

<Clinical Trial Stage> ***) :** "In-house" compounds include a compound generated from collaborative research.

Product Name / Development Code / Generic Name	Classification	Target Indication / Pharmacological Action	Dosage Form	Area	Phase	In-house*) / In-license
ONO-2017 / Cenobamate	New chemical entities	Primary generalized tonic-clonic seizures / Inhibition of voltage-gated sodium currents/positive allosteric modulator of $GABA_A$ ion channel	Tablet	Japan	III	In-license (SK Biopharmaceuticals)
	New chemical entities	Partial-onset seizures / Inhibition of voltage-gated sodium currents/positive allosteric modulator of $GABA_A$ ion channel	Tablet	Japan	III	In-license (SK Biopharmaceuticals)
Velexbru Tablets / Tirabrutinib Hydrochloride	Additional indication	Pemphigus / BTK inhibitor	Tablet	Japan	III	In-house
ONO-2910	New chemical entities	Diabetic polyneuropathy / Schwann cell differentiation promoter	Tablet	Japan	II	In-house
	New chemical entities	Diabetic polyneuropathy / Schwann cell differentiation promoter	Tablet	USA	I	In-house
	New chemical entities	Chemotherapy-induced peripheral neuropathy / Schwann cell differentiation promoter	Tablet	Japan	II	In-house
ONO-2808	New chemical entities	Multiple system atrophy / S1P5 receptor agonist	Tablet	Japan USA	II	In-house
ONO-4685	New chemical entities	Autoimmune disease / PD-1 x CD3 bispecific antibody	Injection	Japan Europe	I	In-house
ONO-2020	New chemical entities	Neurodegenerative disease / Epigenetic regulation	Tablet	USA	I	In-house
ONO-1110	New chemical entities	Pain / Endocannabinoid regulation	Oral	Japan	I	In-house

(6) Main Status of Development Pipelines (Deciphera Pharmaceuticals, Inc.)

As of July 18, 2024

<Clinical Trial Stage> ***) :** "In-house" compounds include a compound generated from collaborative research.

Product Name / Development Code / Generic Name	Classification	Target Indication / Pharmacological Action	Dosage Form	Area	Phase	In-house*) / In-license
QINLOCK / Ripretinib	New chemical entities	Gastrointestinal stromal tumor (fourth line or fourth line plus) / KIT inhibitor	Tablet	North America, Europe, Australia, etc.,	Approved	In-house (Deciphera Pharmaceuticals Inc.)
	Additional indication	Gastrointestinal stromal tumor (second line) / KIT inhibitor	Tablet	North and South America, Europe, Australia, etc.,	III	In-house (Deciphera pharmaceuticals Inc.)
DCC-3014 / Vimseltinib	New chemical entities	Tenosynovial giant cell tumor / CSF-1R inhibitor	Tablet	North America, Europe, Australia, Hong Kong	III	In-house (Deciphera pharmaceuticals Inc.)
DCC-3116	New chemical entities	Solid tumor (in combination with Sotorasib) / ULK inhibitor	Tablet	USA	I/ II	In-house (Deciphera pharmaceuticals Inc.)
	New chemical entities	Solid tumor (in combination with Ripretinib) / ULK inhibitor	Tablet	USA	I/ II	In-house (Deciphera pharmaceuticals Inc.)
DCC-3084	New chemical entities	Solid tumor / Pan-RAF inhibitor	Tablet	USA	I/ II	In-house (Deciphera pharmaceuticals Inc.)